Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.

Zimmer Biomet is taking steps to expand its foot and ankle orthopedics business with a $1.1 billion deal to acquire ...

(Reuters) - Medical device maker Zimmer Biomet Holdings forecast full-year ... due to strong demand for its devices used in hip and knee procedures. Combined sales at Zimmer's hips and knees ...

Barclays lowered the firm’s price target on Zimmer Biomet (ZBH) to $112 from $118 and keeps an Underweight rating on the shares. The firm ...

Despite management's efforts to shift the firm's growth profile, Zimmer Biomet is largely defined by its large joints, which comprise roughly two-thirds of total revenue, and are generally mature ...

Through the $1.1 billion acquisition, Zimmer Biomet expects its sports medicine, extremities and trauma segment to outpace hips and knees, moving forward, according to a Feb. 6 report from Medtech ...

On Thursday, Zimmer Biomet Holdings, Inc (NYSE ... 4.9% on constant currency), beating the consensus of $2.014 billion. Knee product sales increased 5.1% to $839.2 million, and hip product sales ...

Zimmer Biomet Holdings, Inc. ZBH is scheduled to report fourth-quarter 2024 results on Feb. 6, before market open. See the Zacks Earnings Calendar to stay ahead of market-making news. In the last ...